Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37

1.

Liberal or restrictive transfusion in high-risk patients after hip surgery.

Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaupre L, Hildebrand K, Macaulay W, Lewis C, Cook DR, Dobbin G, Zakriya KJ, Apple FS, Horney RA, Magaziner J; FOCUS Investigators.

N Engl J Med. 2011 Dec 29;365(26):2453-62. doi: 10.1056/NEJMoa1012452. Epub 2011 Dec 14.

2.

Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis.

Ren-Heidenreich L, Mordini R, Hayman GT, Siebenlist R, LeFever A.

Cancer Immunol Immunother. 2002 Oct;51(8):417-23. Epub 2002 Jul 23.

PMID:
12202902
3.

A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients.

Lamotte M, Annemans L, Lefever A, Nechelput M, Masure J.

Diabetes Care. 2002 Feb;25(2):303-8.

PMID:
11815500
4.

Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells-phase I clinical trial.

Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP Jr.

J Immunother. 2001 Sep-Oct;24(5):408-19.

PMID:
11696696
5.

Immune Modulation in Cancer Patients After Adoptive Transfer of Anti-CD3/Anti-CD28-Costimulated T Cells-Phase I Clinical Trial.

Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson Jr JP.

J Immunother (1991). 2001 Sep-Oct;24(5):408-419.

PMID:
11685083
6.
7.

Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.

Sen M, Wankowski DM, Garlie NK, Siebenlist RE, Van Epps D, LeFever AV, Lum LG.

J Hematother Stem Cell Res. 2001 Apr;10(2):247-60.

PMID:
11359672
8.

Volunteers--Our greatest natural resource.

LeFever A.

Can J Cardiol. 2001 Apr;17(4):391-3; 396-8. English, French. No abstract available.

PMID:
11329537
9.

A virtual reality surgical trainer for navigation in laparoscopic surgery.

Haluck RS, Webster RW, Snyder AJ, Melkonian MG, Mohler BJ, Dise ML, Lefever A.

Stud Health Technol Inform. 2001;81:171-6.

PMID:
11317733
10.

A balanced reinvestment in health.

Lefever A.

Can J Cardiol. 2000 Nov;16(11):1367-8; 1370-1. English, French. No abstract available.

PMID:
11109033
11.

Prescription attitudes among gynecologists towards two particular risk factors of osteoporosis: the patient's age and her bone mineral density.

Rozenberg S, Lefever A, Kroll M, Vandromme J, Paesmans M, Ham H.

Maturitas. 1999 May 31;32(1):19-24.

PMID:
10423712
12.

T cells coactivated with immobilized anti-CD3 and anti-CD28 as potential immunotherapy for cancer.

Garlie NK, LeFever AV, Siebenlist RE, Levine BL, June CH, Lum LG.

J Immunother. 1999 Jul;22(4):336-45.

PMID:
10404435
13.

The determination of endotoxin in the finished cellular product.

Keller GN, Berzofsky RN, Burt R, Stefka J, Traynor A, Link C, LeFever A.

Cytotherapy. 1999;1(5):423-8.

PMID:
20443235
14.

Factors influencing the prescription of hormone replacement therapy.

Rozenberg S, Kroll M, Vandromme J, Paesmans M, Lefever A, Ham H.

Obstet Gynecol. 1997 Sep;90(3):387-91.

PMID:
9277649
15.

Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.

Rosenfeld CS, Bolwell B, LeFever A, Taylor R, List A, Fay J, Collins R, Andrews F, Pallansch P, Schuster MW, Resta D, Levitt D, Nemunaitis J.

Bone Marrow Transplant. 1996 Feb;17(2):179-83.

PMID:
8640163
16.
17.

Synthesis and biological evaluation of novel potent antagonists of the bombesin/gastrin releasing peptide receptor.

Mokotoff M, Ren K, Wong LK, LeFever AV, Lee PC.

J Med Chem. 1992 Dec 11;35(25):4696-703.

PMID:
1469698
18.

Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.

LeFever AV, Funahashi A.

Cancer Res. 1991 Oct 15;51(20):5596-601.

19.
20.

Lymphokine-activated killer cell activity in lung cancer.

LeFever A, Funahashi A.

Chest. 1991 Feb;99(2):292-7.

PMID:
1989785

Supplemental Content

Loading ...
Support Center